RT Journal Article
SR Electronic
T1 Chemosensitivity Testing of a Novel Platinum Analog, Nedaplatin (254-S), in Human Gynecological Carcinomas: a Comparison with Cisplatin
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4499
OP 4502
VO 25
IS 6C
A1 MASAFUMI KOSHIYAMA
A1 MASANORI KINEZAKI
A1 TAKAFUMI UCHIDA
A1 MASAHIRO SUMITOMO
YR 2005
UL http://ar.iiarjournals.org/content/25/6C/4499.abstract
AB Background: The tetrazolium dye (MTT) assay is useful for predicting chemosensitivity. Materials and Methods: Using the MTT assay, an in vitro chemosensitivity test was designed for nedaplatin (cis-diammine glycolato platinum; 254-S) and the results were compared with the sensitivity to cisplatin in 137 resected gynecological carcinomas. Results: The mean tumor inhibition rate [I.R.; %] for nedaplatin was equal or superior to cisplatin in 15 cervical [70.7% vs. 63.9%], 65 ovarian [61.7% vs. 54.8%] and 57 endometrial carcinomas [52.1% vs. 47.7%]. In ovarian carcinomas, the I.R.s for nedaplatin were significantly higher than cisplatin in poorly-differentiated, serous and endometrioid adenocarcinomas [80.7% vs. 56.4% (p<0.05), 77.0% vs. 64.9% (p<0.01), and 68.2% vs. 54.6% (p<0.05), respectively]. Conclusion: Our data suggest that nedaplatin has equivalent or superior antitumor activity to cisplatin in cervical, ovarian and endometrial carcinomas. In particular, nedaplatin showed a siginificantly better antitumor activity among the histological subtypes of ovarian carcinomas. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved